Amgen Debuts Oncology Biosimilars Bevacizumab And Trastuzumab In US
Executive Summary
Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.
You may also be interested in...
Centus Settles US Litigation Over Avastin
Centus Biotherapeutics and Roche’s Genentech have agreed to settle US patent litigation over the biosimilars firm’s FKB238 proposed bevacizumab rival to Avastin.
Amgen Launches Rituxan Rival In US
Amgen has announced the launch of its biosimilar version of Rituxan (rituximab), Riabni, in the US market, further expanding the firm’s oncology biosimilars portfolio.
US Biosimilars See A Banner Year Despite Few Approvals
With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.